Reference : The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
Scientific journals : Article
Life sciences : Genetics & genetic processes
The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
Paus, Sebastian [> >]
Grünewald, Anne [> >]
Klein, Christine [> >]
Knapp, Michael [> >]
Zimprich, Alexander [> >]
Janetzky, Bernd [> >]
Moller, Jens C. [> >]
Klockgether, Thomas [> >]
Wullner, Ullrich [> >]
Movement Disorders
Yes (verified by ORBilu)
United States
[en] Aged ; Dopamine Agonists/therapeutic use ; Female ; Genotype ; Humans ; Levodopa/therapeutic use ; Male ; Middle Aged ; Parkinson Disease/drug therapy/genetics ; Polymorphism, Genetic/genetics ; Receptors, Dopamine D2/genetics ; Treatment Outcome
[en] Previous studies have demonstrated that the TaqIA polymorphism of the D2 dopamine receptor gene (DRD2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the TaqIA genotype in PD is responsible for demand of dopaminergic medication, measured in total dopaminergic load per year of disease, in a large scale association study based on the gene bank of the German Competence Network on Parkinson's disease. Regression analysis yielded no significant differences between the TaqIA genotypes. We conclude that the DRD2 TaqIA polymorphism alone has no pivotal role for interindividual variability of dopaminergic requirement in PD. We propose a practicable system of measuring dopaminergic treatment for future pharmacogenetic studies in PD.
Researchers ; Students
(c) 2007 Movement Disorder Society.

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.